Medical Research Commercialisation Fund Archives -
Home Tags Medical Research Commercialisation Fund

Tag: Medical Research Commercialisation Fund

University of Melbourne spin-out attracts $14m investment for vaccine to treat gum disease that...

The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL.

A revolution in nanotech helps create a new vaccine delivery system that could literally...

The Nanopatch, a revolutionary new needle-free device for delivering vaccines, has won a $15 million capital injection (pun intended), but also was an award winner at World Vaccine Congress. After eight years of research, the Nanopatch looks set to revolutionise vaccination delivery forever.

Queensland biotech startup Vaxxas gets $15 million from venture funds

Vaxxas Pty. Ltd. has won a $15 million investment from venture groups led by OneVentures. Other investors include Brandon Capital Partners, the Medical Research Commercialisation Fund and U.S.-based HealthCare Ventures. Vaxxas is the first Queensland company to be funded under the Bio Capital Fund, which has swelled to nearly $250 million, established last year with the help of Health Care Ventures and Eli Lilly, among others. The investment was negotiated in the main by UniQuest Pty Limited, the University of Queensland’s main commercialisation company.

FREE BUSINESS TOOLS

FREE BUSINESS TOOL

Five essential ingredients for a humming homepage with James Tuckerman [FREE...

Most homepages dedicate too much of their valuable space to predictable and generally unhelpful information, such as the purpose of the business, their products and services, their achievements and needy invitations to ‘buy, buy, buy’ or ‘contact us for a free consultation on no obligation quote’. Effective homepages focus on the needs and wants of the customer.

INFOGRAPHICS

New Zealand’s Xero eyes US IPO, further disruption as subscribers increase...

Xero recently held its annual meeting in Wellington, during which the company revealed some interesting details about its future. As has been widely suspected, the...

OPINIONS & ADVICE